Considering data from in vitro and in vivo studies, cannabidiol (CBD) seems to be a promising candidate for the treatment of both somatic and psychiatric disorders. The aim of this review was to collect dose(s), dosage schemes, efficacy and safety reports of CBD use in adults from clinical studies. A systematic search was performed in PubMed, Embase and Cochrane library for articles published in English between January 1, 2000 and October 25, 2019. The search terms used were related to cannabis and CBD in adults. We identified 25 studies (927 patients; 538 men and 389 women), of which 22 studies were controlled clinical trials (833 patients) and three were observational designs (94 patients) from five countries. Formulations, dose and dosage schemes varied significantly between studies. Varying effects were identified from the randomized controlled trials (RCTs), more apparent effects from non-RCTs and minor safety issues in general. From the controlled trials, we identified anxiolytic effects with acute CBD administration, and therapeutic effects for social anxiety disorder, psychotic disorder and substance use disorders. In general, studies were heterogeneous and showed substantial risks of bias. Although promising results have been identified, considerable variation in dosage schemes and route of administration were employed across studies. There was evidence to support single dose positive effect on social anxiety disorder, short medium-term effects on symptomatic improvement in schizophrenia and lack of effect in the short mediumterm on cognitive functioning in psychotic disorders. Overall, the administration was well tolerated with mild side effects.

Langerhans' cell histiocytosis (LCH), formerly known as histiocytosis X, is characterized by cell proliferation. The leading clinical symptom of LCH within mandibular and maxillary bones is pain and it may resemble periodontal diseases, apical cysts, ameloblastoma, central giant cell granuloma, vascular malformation, osteomyelitys, bone metastasis and malignancies. In this paper we present the case of a mandibular histiocytosis misdiagnosed as a reparative giant cell granuloma at the first and as an aggressive giant cell tumor at the second biopsy. Definitive diagnosis was made only after examination of surgical specimens following hemimandibulectomy.

Background The aim of the present paper was to evaluate the possibility of determining an individually correct vertical dimension of occlusion (VDO) through the use of surface electromyography (sEMG). Methods A total of 20 patients were prospectively enrolled in this study each requiring an implant prosthetic rehabilitation. For each patient three acquisitions were performed by the use of the electromyograph EasyMyo (TFR Technology, Udine, Italy). The individually correct VDO was achieved by the modification of provisional prosthetics, following the stabilization of indices indicated by the EMGGest software. Results At the time of delivery of the final prosthesis, all the considered indices showed values in the biological range. This means the achievement of an occlusion perfectly integrated in the neuromuscolar individual system and achievement of an individually correct VDO. Discussion Occlusal adjustments of VDO are made guided by the electric muscle activity measured by the sEMG. This procedure can positively affect the implant success rate because in conditions of neuromuscular balance overloading components are reduced

[No abstract available

No abstract